- Home
- NPCT vs EYPT Comparison
NPCT vs EYPT Comparison
Compare NPCT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPCT | EYPT |
|---|---|---|
| Founded | 2020 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.7M | 273.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | NPCT | EYPT |
|---|---|---|
| Price | $9.15 | $0.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $8.44 |
| AVG Volume (30 Days) | 88.5K | ★ 16.2M |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 9.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $126.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.86 | $0.34 |
| 52 Week High | $10.82 | $19.11 |
Technical Indicators
Market Signals| Indicator | NPCT | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 16.73 |
| Support Level | $8.86 | N/A |
| Resistance Level | $9.86 | $3.57 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 72.97 | 5.53 |
Price Performance
Historical ComparisonAbout NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.